{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:40:30Z","timestamp":1792795230099,"version":"4.5.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not completely effective, and concerns about the risk of bleeding continue to limit their uptake. Animal studies and experience from patients with genetic coagulation factor XI deficiency suggesting that this factor is more important for thrombosis than for haemostasis raises the potential for drugs that target factor XI to provide safer anticoagulation. Multiple factor XI inhibitors are currently under evaluation in clinical trials, including parenterally administered antisense oligonucleotides, monoclonal antibodies, and orally active small-molecule inhibitors. Promising results of phase 2 trials in patients undergoing major orthopaedic surgery, and in those with end-stage kidney disease, atrial fibrillation and acute coronary syndromes have led to large phase 3 trials that are currently ongoing. We here review premises for the use of these agents, results so far accrued, ongoing studies, and perspectives for future patient care.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac464","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:01:18Z","timestamp":1666260078000},"page":"280-292","source":"Crossref","is-referenced-by-count":66,"title":["Factor XI inhibitors: cardiovascular perspectives"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"first","affiliation":[{"name":"Chair of Cardiology, University of Pisa and Division of Cardiology, Pisa University Hospital , Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-2386","authenticated-orcid":false,"given":"Domenico","family":"Prisco","sequence":"additional","affiliation":[{"name":"Chair of Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence and Careggi University Hospital , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences , Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2023012107594860600_ehac464-B1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"key":"2023012107594860600_ehac464-B6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2023012107594860600_ehac464-B7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.21037\/atm.2017.06.65","article-title":"Direct oral anticoagulants: analysis of worldwide use and popularity using google trends","volume":"5","author":"Lippi","year":"2017","journal-title":"Ann Transl Med"},{"key":"2023012107594860600_ehac464-B10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B11","doi-asserted-by":"crossref","first-page":"102711","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023012107594860600_ehac464-B12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2023012107594860600_ehac464-B13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"2023012107594860600_ehac464-B14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euv288","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial","volume":"18","author":"De Caterina","year":"2016","journal-title":"Europace"},{"key":"2023012107594860600_ehac464-B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ahj.2020.03.018","article-title":"The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation","volume":"225","author":"Karthikeyan","year":"2020","journal-title":"Am Heart J"},{"key":"2023012107594860600_ehac464-B16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3181\/00379727-82-20057","article-title":"New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor","volume":"82","author":"Rosenthal","year":"1953","journal-title":"Proc Soc Exp Biol Med"},{"key":"2023012107594860600_ehac464-B17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V85.2.429.429","article-title":"One of the two common mutations causing factor XI deficiency in ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews","volume":"85","author":"Shpilberg","year":"1995","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B18","doi-asserted-by":"crossref","first-page":"e2010025","DOI":"10.4084\/mjhid.2010.025","article-title":"Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, Egypt: retrospective analysis","volume":"2","author":"Tonbary","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2023012107594860600_ehac464-B19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"2023012107594860600_ehac464-B20","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1161\/01.ATV.20.11.2489","article-title":"Activation of clotting factors XI and IX in patients with acute myocardial infarction","volume":"20","author":"Minnema","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023012107594860600_ehac464-B21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of factor XIa and plasma kallikrein in arterial and venous thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"Thromb Haemost"},{"key":"2023012107594860600_ehac464-B22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023012107594860600_ehac464-B23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2023012107594860600_ehac464-B24","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023012107594860600_ehac464-B27","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/JCI781","article-title":"Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor","volume":"101","author":"Minnema","year":"1998","journal-title":"J Clin Invest"},{"key":"2023012107594860600_ehac464-B29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2023012107594860600_ehac464-B30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"2023012107594860600_ehac464-B31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2023012107594860600_ehac464-B32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"2023012107594860600_ehac464-B33","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41598-017-02055-x","article-title":"Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa","volume":"7","author":"Donkor","year":"2017","journal-title":"Sci Rep"},{"key":"2023012107594860600_ehac464-B34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb Res"},{"key":"2023012107594860600_ehac464-B35","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.3390\/ijms22083897","article-title":"Overview of the therapeutic potential of aptamers targeting coagulation factors","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023012107594860600_ehac464-B36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood.V118.21.209.209","article-title":"ISIS-FXIRx, A novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, A fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2023012107594860600_ehac464-B38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2023012107594860600_ehac464-B39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023012107594860600_ehac464-B40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"key":"2023012107594860600_ehac464-B41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2023012107594860600_ehac464-B42","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2023012107594860600_ehac464-B43","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2023012107594860600_ehac464-B44","doi-asserted-by":"crossref","first-page":"821363","DOI":"10.3389\/fphar.2022.821363","article-title":"First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of SHR2285, a small-molecule factor xIa inhibitor in healthy subjects","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023012107594860600_ehac464-B45"},{"key":"2023012107594860600_ehac464-B46","doi-asserted-by":"crossref","first-page":"e0196","DOI":"10.1097\/CCE.0000000000000196","article-title":"EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report","volume":"2","author":"Pollack","year":"2020","journal-title":"Crit Care Explor"},{"key":"2023012107594860600_ehac464-B47","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","article-title":"First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects","volume":"84","author":"Perera","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2023012107594860600_ehac464-B48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2019.04.019","article-title":"Modulation of the mammalian coagulation system by venoms and other proteins from snakes, arthropods, nematodes and insects","volume":"178","author":"Sachetto","year":"2019","journal-title":"Thromb Res"},{"key":"2023012107594860600_ehac464-B49","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20091007","article-title":"Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis","volume":"206","author":"Decrem","year":"2009","journal-title":"J Exp Med"},{"key":"2023012107594860600_ehac464-B50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.2019000919","article-title":"Novel antithrombotic strategies for treatment of venous thromboembolism","volume":"135","author":"Weitz","year":"2020","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B53","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B54","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.thromres.2015.10.009","article-title":"Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis","volume":"136","author":"Feng","year":"2015","journal-title":"Thromb Res"},{"key":"2023012107594860600_ehac464-B55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2016-09-692996","article-title":"Emerging anticoagulant strategies","volume":"129","author":"Fredenburgh","year":"2017","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B56","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1055\/s-0041-1736037","article-title":"Management of cancer-associated thrombosis: unmet needs and future perspectives","volume":"5","author":"Falanga","year":"2021","journal-title":"TH Open"},{"key":"2023012107594860600_ehac464-B57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2023012107594860600_ehac464-B58","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B59","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"key":"2023012107594860600_ehac464-B60","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/13543784.2021.1897786","article-title":"Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation","volume":"30","author":"Bentley","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2023012107594860600_ehac464-B61","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney Int"},{"key":"2023012107594860600_ehac464-B62","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with End-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2023012107594860600_ehac464-B63","doi-asserted-by":"crossref","first-page":"10.1002\/rht2.12509","DOI":"10.1002\/rth2.12509","article-title":"Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition","volume":"5","author":"Mavromanoli","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2023012107594860600_ehac464-B64","first-page":"1116","article-title":"Pharmacokinetics and pharmacodynamics of ionis-FXIRx, an antisense inhibitor of factor XI, in patients with End-stage renal disease on hemodialysis","volume":"130","author":"Bethune","year":"2017","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(rx) in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023012107594860600_ehac464-B66","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B67","doi-asserted-by":"crossref","first-page":"e0137444","DOI":"10.1371\/journal.pone.0137444","article-title":"Risk of fatal bleeding in episodes of Major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis","volume":"10","author":"Skaistis","year":"2015","journal-title":"PLoS One"},{"key":"2023012107594860600_ehac464-B68","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/ene.13742","article-title":"Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis","volume":"25","author":"Katsanos","year":"2018","journal-title":"Eur J Neurol"},{"key":"2023012107594860600_ehac464-B69","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.120.049768","article-title":"Stroke prevention in atrial fibrillation: looking forward","volume":"142","author":"Katsanos","year":"2020","journal-title":"Circulation"},{"key":"2023012107594860600_ehac464-B70","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"2023012107594860600_ehac464-B71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xIa inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"2023012107594860600_ehac464-B72","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"2023012107594860600_ehac464-B73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/2040620717733691","article-title":"The role of oral anticoagulant therapy in patients with acute coronary syndrome","volume":"8","author":"Moon","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"2023012107594860600_ehac464-B74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2023012107594860600_ehac464-B75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","article-title":"Antithrombotic agents","volume":"124","author":"Chan","year":"2019","journal-title":"Circ Res"},{"key":"2023012107594860600_ehac464-B76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13054-020-02925-3","article-title":"COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review","volume":"24","author":"Kowalewski","year":"2020","journal-title":"Crit Care"},{"key":"2023012107594860600_ehac464-B77","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14779072.2020.1773803","article-title":"Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices","volume":"18","author":"den Exter","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2023012107594860600_ehac464-B78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023012107594860600_ehac464-B79","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"2023012107594860600_ehac464-B80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/4\/280\/48807026\/ehac464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/4\/280\/48807026\/ehac464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T08:00:40Z","timestamp":1674288040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/4\/280\/6763814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2023,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac464","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,21]]},"published":{"date-parts":[[2022,10,20]]}}}